[1] Sung KC, Rhee EJ, Ryu S, et al. Increased Cardiovascular Mortality in Subjects With Metabolic Syndrome Is Largely Attributable to Diabetes and Hypertension in 159, 971 Korean Adults. J Clin Endocrinol Metab, 2015; 100, 2606-12. doi:  10.1210/jc.2014-4031
[2] Lu J, Wang L, Li M, et al. Metabolic Syndrome Among Adults in China:The 2010 China Noncommunicable Disease Surveillance. J Clin Endocrinol Metab, 2017; 102, 507-15.
[3] Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol, 2011; 11, 85-97. doi:  10.1038/nri2921
[4] Watanabe K, Yamada H, Yamaguchi Y. K-glypican:a novel GPI-anchored heparan sulfate proteoglycan that is highly expressed in developing brain and kidney. J Cell Biol, 1995; 130, 1207-18. http://d.old.wanfangdata.com.cn/Periodical/sygzbzz201305007
[5] Ussar S, Bezy O, Bluher M, et al. Glypican-4 enhances insulin signaling via interaction with the insulin receptor and serves as a novel adipokine. Diabetes, 2012; 61, 2289-98. doi:  10.2337/db11-1395
[6] Tamori Y, Kasuga M. Glypican-4 is a new comer of adipokines working as insulin sensitizer. J Diabetes Investig, 2013; 4, 250-1. doi:  10.1111/jdi.2013.4.issue-3
[7] Yoo HJ, Hwang SY, Cho GJ, et al. Association of glypican-4 with body fat distribution, insulin resistance, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab, 2013; 98, 2897-901. doi:  10.1210/jc.2012-4297
[8] Zhu HJ, Pan H, Cui Y, et al. The changes of serum glypican4 in obese patients with different glucose metabolism status. J Clin Endocrinol Metab, 2014; 99, E2697-701. doi:  10.1210/jc.2014-2018
[9] Alberti KG, Zimmet P, Shaw J. The metabolic syndrome——a new worldwide definition. Lancet, 2005; 366, 1059-62. doi:  10.1016/S0140-6736(05)67402-8
[10] Jedrzejuk D, Lwow F, Kuliczkowska-Plaksej J, et al. Association of serum glypican-4 levels with cardiovascular risk predictors in women with polycystic ovary syndrome-a pilot study. Gynecol Endocrinol, 2016; 32, 223-6. doi:  10.3109/09513590.2015.1110137
[11] Li K, Xu X, Hu W, et al. Glypican-4 is increased in human subjects with impaired glucose tolerance and decreased in patients with newly diagnosed type 2 diabetes. Acta Diabetol, 2014; 51, 981-90. doi:  10.1007/s00592-014-0652-5
[12] Leelalertlauw C, Korwutthikulrangsri M, Mahachoklertwattana P, et al. Serum glypican 4 level in obese children and its relation to degree of obesity. Clin Endocrinol (Oxf), 2017; 87, 689-95. doi:  10.1111/cen.2017.87.issue-6
[13] Lee SA, Koh G, Cho SJ, et al. Correlation of Glypican-4 Level with Basal Active Glucagon-Like Peptide 1 Level in Patients with Type 2 Diabetes Mellitus. Endocrinol Metab (Seoul), 2016; 31, 439-45. doi:  10.3803/EnM.2016.31.3.439